Treace Medical Concepts (TMCI) Liabilities and Shareholders Equity (2020 - 2026)

Treace Medical Concepts has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $184.1 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 10.56% year-over-year to $184.1 million; the trailing twelve-month figure through Mar 2026 stood at $777.7 million (down 9.77% YoY), and the FY2025 full-year result was $190.6 million, down 12.21% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $184.1 million, down from $190.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $251.9 million in Q4 2023, with the low at $146.5 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $205.5 million across 5 years, with a median of $206.4 million in 2025.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 291.93% — and 2025, when it fell 15.19%.
• Treace Medical Concepts' Liabilities and Shareholders Equity stood at $159.0 million in 2022, then soared by 58.41% to $251.9 million in 2023, then fell by 13.82% to $217.1 million in 2024, then dropped by 12.21% to $190.6 million in 2025, then declined by 3.4% to $184.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $184.1 million (Q1 2026), $190.6 million (Q4 2025), and $196.6 million (Q3 2025), per Business Quant data.